Severe infection in children
Conditions
Interventions
experimental group:Vancomycin was monitored using AUC
control group:Vancomycin was monitored using Cmin
Sponsors
Children's Hospital of Chongqing Medical University
Eligibility
Sex/Gender
All
Age
0.1 Years to 16 Years
Inclusion criteria
Inclusion criteria: 1. Age 28 days to 16 years old; 2. Clinical or laboratory diagnosis of Gram-positive bacterial infection; 3. Use vancomycin for >= 72 hours and monitor the serum trough and peak concentrations of vancomycin; 4. The informed consent has been signed.
Exclusion criteria
Exclusion criteria: 1. Those who have received teicoplanin, linezolid, rifampicin and other antibacterial drugs for more than 24 hours within 72 hours before treatment; 2. The time of using vancomycin is less than 72h; 3. Intravenous use of vancomycin; 4. Carry out blood purification treatment; 5. Combined use of other nephrotoxic drugs, such as aminoglycosides, amphotericin and cyclosporine; 6. Incomplete clinical data; 7. Vancomycin is resistant, allergic, or has stopped taking drugs due to adverse reactions during use; 8. Abnormal hearing.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical curative effect; | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse reactions;28-day case fatality rate; | — |
Countries
China
Contacts
Public ContactChengjun Liu
Children's Hospital of Chongqing Medical University
Outcome results
None listed